{"html":"<iframe style=\"border-radius: 12px\" width=\"100%\" height=\"152\" title=\"Spotify Embed: FDA D.I.S.C.O. Burst Edition: FDA approval of Ryoncil (remestemcel-L-rknd) for steroid-refractory acute graft versus host disease in pediatric patients\" frameborder=\"0\" allowfullscreen allow=\"autoplay; clipboard-write; encrypted-media; fullscreen; picture-in-picture\" loading=\"lazy\" src=\"https://open.spotify.com/embed/show/14O7ZkkvuFWaYDD4wuOBil?utm_source=oembed\"></iframe>","iframe_url":"https://open.spotify.com/embed/show/14O7ZkkvuFWaYDD4wuOBil?utm_source=oembed","width":456,"height":152,"version":"1.0","provider_name":"Spotify","provider_url":"https://spotify.com","type":"rich","title":"FDA D.I.S.C.O. Burst Edition: FDA approval of Ryoncil (remestemcel-L-rknd) for steroid-refractory acute graft versus host disease in pediatric patients","thumbnail_url":"https://image-cdn-fa.spotifycdn.com/image/ab67656300005f1f17ac883398e142c83c298c34","thumbnail_width":300,"thumbnail_height":300}